The EMulate Therapeutics Voyager® ulRFE® system is a non-invasive medical device. It is the first of many product expressions of the company’s underlying ulRFE platform technology. Showing promise in pre-clinical and clinical trials, the EMulate Therapeutics Voyager® has potential treatment applications in a wide range of diseases, including cancer, chronic pain, inflammatory, among others. The EMulate Therapeutics Voyager device is being evaluated for the treatment of glioblastoma multiforme (GBM) brain tumors in human clinical trials.
Note: EMulate Therapeutics Voyager ulRFE® system for GBM is an investigational medical device. Limited by Federal United States law to investigational use only.
Every molecule has a specific and unique electrostatic surface potential. Electrostatic surface potential is a critically important property of a molecule; it is a key factor in how a molecule interacts with (and in) a biological system. For the first time ever, the ultra-low radio frequency energy (ulRFE) profiles produced by changes in molecular electrostatic surface potential can be measured and recorded by our ‘Super Conducting Quantum Interference Device’ (SQUID)-based technology (more info on SQUID>). Applying these highly precise ulRFE profiles (cognates) to biological systems produce precise biological responses. It is theorized that transduction of these cognates induce changes in the intended target, thus altering cell dynamics and producing biological effects.